Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Overview of Dr. Strosberg
Dr. Jonathan Strosberg is an oncologist at the Moffitt Cancer Center in Tampa, FL, with specialized expertise in neuroendocrine cancers. Dr. Strosberg has contributed to the field through multiple publications on neuroendocrine tumors, with his research being featured in esteemed journals such as The New England Journal of Medicine. Additionally, he has played significant roles in various clinical trials focusing on innovative treatments for neuroendocrine tumors.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2003 - 2006
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1999 - 2002
Weill Cornell MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2003 - 2027
DC State Medical License 2002 - 2004
MT State Medical License 2003 - 2004
VA State Medical License 2000 - 2004
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2014, 2016
- CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2014, 2016
- CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2014, 2016
Clinical Trials
- Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) Start of enrollment: 2003 Oct 01
- Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Start of enrollment: 2006 Nov 01
- Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) Start of enrollment: 2006 Oct 01
Publications & Presentations
PubMed
- Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine T...Christophe M Deroose, Hannes Leupe, Rodney J Hicks, Irene Virgolini, Arthur J A T Braat
The Lancet. Oncology. 2026-07-03 - [Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.Thomas Walter, Henning Jann, Catherine Ansquer, Emmanuel Deshayes, Rocio Garcia-Carbonero
Lancet. 2026-07-02 - Somatostatin Receptor Expression on [Ga]Ga-DOTATATE PET Among Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas: A Prospective Study.Jonathan R Strosberg, Taymeyah Al-Toubah, Mintallah Haider, Ghassan El-Haddad, Jaime Montilla-Soler
Journal of Nuclear Medicine. 2026-06-11
Lectures
- Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.2019 ASCO Annual Meeting - 6/1/2019
- Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- Gastroenteropancreatic Neuroendocrine TumorsJonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-10-31 - Gastroenteropancreatic Neuroendocrine TumorsJonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-11-21 - Gastroenteropancreatic Neuroendocrine TumorsJonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-11-21
Press Mentions
Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025May 22nd, 2025- ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-Edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 ConferenceMarch 6th, 2025
- 'Clinically Meaningful' Survival Gain in Neuroendocrine TumorsJuly 1st, 2021
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access Choice PPO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
Anthem Blue Preferred Select
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA HMOCIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
